TNFSF13 and systemic lupus erythematosus: For instance, conditions like systemic lupus erythematosus and Sjögren’s syndrome, where abnormal B cell proliferation and autoantibody production are core features, could see improved patient outcomes through combined BAFF and APRIL inhibition (203).